206 related articles for article (PubMed ID: 2454375)
1. Pharmacokinetics and disposition of carvedilol in humans.
Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker.
von Möllendorff E; Reiff K; Neugebauer G
Eur J Clin Pharmacol; 1987; 33(5):511-3. PubMed ID: 3428345
[TBL] [Abstract][Full Text] [Related]
5. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans.
Neugebauer G; Wittenbrink-Dix AM; Woelke-Seidl E; Kaufmann B; Ponton T; Dahmen W; Mosberg H; Nieder N; Besenfelder E
Arzneimittelforschung; 1989 Oct; 39(10A):1336-9. PubMed ID: 2576358
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characteristics of bornaprolol in healthy volunteers.
Cheymol G; Cheymol A; Jozefczak C; Lecoq V; Lecoq B; Jaillon P
Xenobiotica; 1990 Aug; 20(8):855-60. PubMed ID: 1977241
[TBL] [Abstract][Full Text] [Related]
9. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction.
Neugebauer G; Gabor M; Reiff K
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S142-6. PubMed ID: 1378143
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of carvedilol in man.
Neugebauer G; Neubert P
Eur J Drug Metab Pharmacokinet; 1991; 16(4):257-60. PubMed ID: 1823868
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.
Regårdh CG; Lundborg P; Gabrielsson M; Heggelund A; Kylberg-Hanssen K
Pharm Res; 1990 Dec; 7(12):1222-7. PubMed ID: 1982773
[TBL] [Abstract][Full Text] [Related]
15. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
16. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
